Our Vision
Safe and effective precision diagnostics are essential to quality healthcare.
What We Do
Inmedix secured FDA clearance for its CloudHRV® System diagnostic in January 2025.
CloudHRV is cleared as a 5-min, medical-grade heart rate variability (HRV) diagnostic to be used in the clinical setting at the discretion of medical caregivers. CloudHRV reports the two primary aspects of autonomic nervous system (ANS) neuroregulatory control within the human brain: the parasympathetic (rest/restorative) component and the sympathetic (fight-or-fight) component.
Inmedix is laser focused on understanding the ANS and aspires to discerning its role in human physiology and illness.
Discovery is difficult, but we believe it's more than possible and we're working hard to make it happen.
More About Inmedix View Our Team
Our story
Inmedix Timeline
2001
2003
2004
2006
2007
2008
2013
2014
2015
2016
2017
2018
2020
2021
2022
2024
2025
ANS stress, FM and RA activity linked at EULAR meeting in Stockholm.
HRV linked with FM severity and effective TNFi treatment of RA at BSR meeting in Edinburgh.
First successful RCT of dopamine agonists to treat FM at ACR meeting in San Antonio.
Inmedix founded as a patent holding company.
Sale of dopamine agonist – FM international Inmedix patents.
First predictive ECG biomarker (HRV) for TNFi therapy.
Inmedix converts from a patent holding to a diagnostic/therapeutic company.
Inmedix builds commercial team.
First successful pilot study to enhance TNFi with ANS optimization.
Inmedix meets with FDA for the first of five Qsub meetings.
Inmedix UK Ltd subsidiary established, converts to Inmedix Inc and flied first ANS Therapeutics patent.
Research prototype created for clinical studies
Expanded research in COVID and long COVID
Created executive team from diagnostic industry experts
FDA clears Inmedix CloudHRV for US commercialization
